{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T13:37:16Z","timestamp":1781357836427,"version":"3.54.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1097\/wnf.0b013e3180ca77ea","type":"journal-article","created":{"date-parts":[[2008,5,28]],"date-time":"2008-05-28T07:12:50Z","timestamp":1211958770000},"page":"127-133","source":"Crossref","is-referenced-by-count":54,"title":["A Study of Chorea After Tetrabenazine Withdrawal in Patients With Huntington Disease"],"prefix":"10.1097","volume":"31","author":[{"given":"Samuel","family":"Frank","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Ondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Fahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Oakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Plumb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Shoulson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Eberly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Factor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Shinaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 5","key":"R1-1-20210203","first-page":"A204","article-title":"CARE-HD Investigators of the Huntington Study Group. Functional decline due to chorea in Huntington's disease.","volume":"62","author":"Frank","year":"2004","journal-title":"Neurology"},{"issue":"654","key":"R3-1-20210203","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/bmj.2.5654.422","article-title":"Effect of tetrabenazine on extrapyramidal movement disorders.","volume":"2","author":"Dalby","year":"1969","journal-title":"Br Med J"},{"key":"R4-1-20210203","first-page":"277","article-title":"Tetrabenazine in the treatment of hyperkinetic movement disorders.","volume":"37","author":"Jankovic","year":"1983","journal-title":"Adv Neurol"},{"issue":"3","key":"R5-1-20210203","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1212\/WNL.38.3.391","article-title":"Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.","volume":"38","author":"Jankovic","year":"1988","journal-title":"Neurology"},{"issue":"2","key":"R6-1-20210203","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.48.2.358","article-title":"Long-term effects of tetrabenazine in hyperkinetic movement disorders.","volume":"48","author":"Jankovic","year":"1997","journal-title":"Neurology"},{"issue":"9","key":"R7-1-20210203","first-page":"871","article-title":"Drug treatment of diseases characterized by abnormal movements.","volume":"66","author":"Marsden","year":"1973","journal-title":"Proc R Soc Med"},{"issue":"5","key":"R8-1-20210203","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.wnf.0000136892.24629.96","article-title":"Tetrabenazine treatment in movement disorders.","volume":"27","author":"Paleacu","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"R9-1-20210203","first-page":"267","article-title":"Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.","volume":"37","author":"Fahn","year":"1983","journal-title":"Adv Neurol"},{"issue":"1","key":"R10-1-20210203","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1586\/14737175.6.1.7","article-title":"Tetrabenazine in the treatment of hyperkinetic movement disorders.","volume":"6","author":"Kenney","year":"2006","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"R11-1-20210203","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial.","volume":"66","year":"2006","journal-title":"Neurology"},{"issue":"19","key":"R12-1-20210203","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/0006-2952(83)90388-X","article-title":"Differential interactions of phencyclidine with tetrabenazine and reserpine affecting intraneuronal dopamine.","volume":"32","author":"Bagchi","year":"1983","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"R13-1-20210203","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0014-2999(69)90183-6","article-title":"Effects of apomorphine and amphetamine on schedule-controlled behavior: reversal of tetrabenazine suppression and dopaminergic correlates.","volume":"6","author":"Butcher","year":"1969","journal-title":"Eur J Pharmacol"},{"key":"R14-1-20210203","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0022-3565(25)25665-8","article-title":"Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects.","volume":"127","author":"Quinn","year":"1959","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"R15-1-20210203","first-page":"221","article-title":"Binding of a tetrabenazine derivative to the monoamine transporter of the chromaffin granule membrane InFrench.","volume":"293","author":"Scherman","year":"1981","journal-title":"C R Seances Acad Sci III"},{"issue":"2","key":"R16-1-20210203","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1212\/WNL.36.2.244","article-title":"Huntington's disease in Venezuela: neurologic features and functional decline.","volume":"36","author":"Young","year":"1986","journal-title":"Neurology"},{"issue":"pt 5","key":"R19-1-20210203","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/brain\/116.5.1201","article-title":"Neurochemical substrates of rigidity and chorea in Huntington's disease.","volume":"116","author":"Storey","year":"1993","journal-title":"Brain"},{"issue":"6","key":"R20-1-20210203","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00002826-200211000-00003","article-title":"Tetrabenazine treatment for Huntington's disease-associated chorea.","volume":"25","author":"Ondo","year":"2002","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"R21-1-20210203","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington's Disease Rating Scale: reliability and consistency.","volume":"11","year":"1996","journal-title":"Mov Disord"},{"issue":"5","key":"R22-1-20210203","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1212\/WNL.50.5.1366","article-title":"Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease.","volume":"50","year":"1998","journal-title":"Neurology"},{"issue":"5","key":"R24-1-20210203","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1006\/pmed.1996.0124","article-title":"The nocebo phenomenon: concept, evidence, and implications for public health.","volume":"26","author":"Hahn","year":"1997","journal-title":"Prev Med"},{"issue":"6","key":"R25-1-20210203","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/BF00615962","article-title":"The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders.","volume":"29","author":"Roberts","year":"1986","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002826-200805000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T12:49:09Z","timestamp":1738241349000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-200805000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3180ca77ea","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}